Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
PLX Stock Chart & Stats
$2.89
-$0.05(-2.01%)
At close: 4:00 PM EST
$2.89
-$0.05(-2.01%)
Day’s Range― - ―
52-Week Range$1.32 - $3.10
Previous CloseN/A
Volume368.29K
Average Volume (3M)1.13M
Market Cap
$232.42M
Enterprise Value$218.91M
Total Cash (Recent Filing)$29.37M
Total Debt (Recent Filing)$8.18M
Price to Earnings (P/E)40.3
Beta0.60
Next Earnings
Mar 12, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding80,421,180
10 Day Avg. Volume1,908,038
30 Day Avg. Volume1,130,904
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)3.16
Price to Sales (P/S)2.55
P/FCF Ratio18.45
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.54
Enterprise Value/Gross Profit6.15
Enterprise Value/Ebitda24.68
Forecast
1Y Price Target
$12.00Price Target Upside315.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial AdvantageLess frequent dosing for Elfabrio creates a meaningful commercial advantage for patients with a chronic condition, improving convenience and supporting the drug's attractiveness versus existing enzyme therapies to capture market share.
Regulatory OpinionEMA committee's positive opinion recommending approval of a monthly dosing regimen for Elfabrio in adults stable on enzyme replacement therapy increases the likelihood of broader regulatory acceptance and expands treatment choices for patients with Fabry disease.
Strategic Collaboration And PipelineCollaboration with Secarna using an AI-driven discovery platform, combined with an option for an exclusive, milestone-and-royalty-bearing license, enhances development prospects for novel renal therapies and adds potential future revenue streams.
Bears Say
Competitive LandscapeEstablished enzyme therapies in the European market could limit the speed and extent of Elfabrio's adoption, constraining potential sales growth in the region.
Milestone Timing And Cash OutlookSlower-than-expected market uptake may delay achievement of regulatory-linked milestone payments from the partner, putting pressure on Protalix's cash outlook.
Reimbursement And Access RiskPayer reluctance to switch patients from incumbent therapies could create reimbursement barriers that restrict real-world access even after regulatory approval.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.32 and its highest was $3.10 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $232.42M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 30 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Nov 13, 2025. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.055 by -$0.025.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is 0.04.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,421,180 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.03 in its last earnings report, missing expectations of $0.055. Following the earnings report the stock price went down -9.813%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (315.22% Upside)
$12.00 (315.22% Upside)
Blogger Sentiment
Bullish
PLX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $101.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.43%
12-Months-Change
Fundamentals
Return on Equity
12.64%
Trailing 12-Months
Asset Growth
33.63%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
PLX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong year-to-date revenue growth and advancement in clinical trials, alongside a positive Q3 net income and solid cash position. However, there were challenges, including a slight decrease in Q3 revenue, increased R&D expenses, and regulatory uncertainty regarding Elfabrio's dosing regimen in Europe.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$12.00
▲(315.22% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.88% Insiders
2.63% Mutual Funds
4.57% Other Institutional Investors
85.10% Public Companies and Individual Investors